Epigral Ltd
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Epigral Limited's management has expressed a cautiously optimistic outlook for FY27, driven by strategic capacity expansions in CPVC Resin and Epichlorohydrin, which are expected to enhance market share and revenue growth. The company targets a volume growth of 10% to 12%, leveraging its diversified product portfolio and integrated manufacturing capabilities. However, geopolitical tensions, particularly the US-Israel-Iran conflict, pose risks to supply chains and raw material costs, which could impact profitability. Vista's financial outlook reflects stable revenue growth and margins, supported by a strong balance sheet and fair valuation. The anticipated completion of capacity expansions by Q2 FY27 aligns with Vista's expectations for a 20% revenue CAGR, although execution risks remain a concern. The specialty chemicals industry is experiencing structural growth, bolstered by domestic demand and favorable trade conditions, which should benefit Epigral. Over the next 12-24 months, key opportunities include successful project execution and new greenfield initiatives, while headwinds may arise from volatile raw material prices and regulatory compliance challenges
Why We Like This Stock
- Strategic capacity expansions in CPVC Resin and Epichlorohydrin expected to drive revenue growth
- Diversified product portfolio provides resilience against market volatility
- Strong balance sheet supports ongoing investments and operational efficiencies
Things To Watch Out For
- Geopolitical tensions could disrupt supply chains and increase costs
- Execution risks related to ramping up new capacities may impact profitability
- Volatile raw material prices and regulatory compliance pose ongoing challenges
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,929 | 2,550 | 2,527 | 2,586 | 2,649 |
| Profit Before Tax (Cr.) | 291 | 534 | 342 | 363 | 368 |
| PBT Margin | 15.1% | 20.9% | 1353.4% | 14.0% | 13.9% |
| Net Profit (Cr.) | 238 | 438 | 257 | 271 | 276 |
| Earnings Per Share | 55.3 | 101.7 | 59.7 | 63.0 | 63.9 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Epigral Limited manufactures and sells chlor-alkali and derivative products in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resin, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda and potash, chlorine, hydrogen, chloromethanes, captive power plant (CPP), and chlorotoluene value chain, as well as operates wind-solar hybrid power plant. Its products are used in CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited in August 2023. Epigral Limited was incorporated in 2007 and is based in Ahmedabad, India.